Treatment of von Willebrand disease

International Journal of Clinical and Laboratory Research

Volumn 28, Issue 4, 1998, Pages 211-214

  Mannucci, P M ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE   (Italy)

Author keywords

Desmopressin; Plasma concentrates; Von Willebrand disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR 8; HEMOSTATIC AGENT; VON WILLEBRAND FACTOR;

HUMAN; REVIEW; VON WILLEBRAND DISEASE;

ANTIFIBRINOLYTIC AGENTS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HEMOSTATICS; HUMANS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0032426513     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005990050047     Document Type: Review

References (33)

1. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30:81.
2. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Blood 1997; 90: 2515.
3. Mannucci PM, Bettega D, Cattaneo M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br J. Haematol 1992; 82:87.
4. Smith TJ, Gill JC, Ambroso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199.
5. Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med 1988; 318: 121.
6. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28:63.
7. Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, Mazzucconi MG, Mariani G. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66:796.
8. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease. N Engl J Med 1983; 309:816.
9. Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease. Blood 1989; 74: 1859.
10. Mazurier C, Gaucher C, Jorieux S, Goudemand M, the Collaborative Group. Biological effect of desmopressin in eight patients with type 2 N ('Normandy') von Willebrand disease. Br J Haematol 1994; 88:849.
11. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol 1994; 89:849.
12. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245.
13. Perkins HA. Correction of the hemostatic defects in von Willebrand disease. Blood 1967; 30:375.
14. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193.
15. Cornu P, Larrieu MJ, Caen J, Bernard J. Transfusion studies in von Willebrand disease: effect on bleeding time and factor VIII. Br J Haematol 1963; 9: 189.
16. Mannucci PM, Tenconi PM, Castaman F, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130.
17. Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83:3018.
18. Cattaneo M, Moia M, Della Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989; 74: 1972.
19. Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in von Willebrand disease. Blood 1991; 77: 1901.
20. Castillo R, Escolar G, Monteagudo J, Aznar-Salatti J, Reverter JC, Ordinas A. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997; 37:785.
21. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995; 92:2428.
22. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80:214.
23. Menache D, Aronson DL, Darr F, Montgomery R and the Cooperative Study Group. Pharmacokinetics of von Willebrand factor and factor VIII in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIII synthesis. Br J Haematol 1996; 94:740.
24. Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68:282.
25. Pareti FI, Federici AB, Cattaneo M, Mannucci PM. Spontaneous platelet aggregation during pregnancy in a patient with VWD type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol 1990; 75:86.
26. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to FVIII/von Willebrand factor in von Willebrand disease: effects on replacement therapy. Blood 1981; 57:25.
27. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125:348.
28. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici AB, Altieri D, Tedesco F. Life-threatening reaction to FVIII concentrate in a patient with severe VWD and alloantibodies to von Willebrand factor. Eur J Haematol 1987; 39:467.
29. Biggs R, Matthews JM. The treatment of hemorrhage in von Willebrand's disease and the blood levels of factor VIII (AHG). Br J Haematol 1963; 9:203.
30. Larrieu MJ, Caen JP, Vainer MH, Sultan Y, Bernard J. Congenital bleeding disorders with long bleeding time and normal platelet count. Am J Med 1968; 45:354.
31. Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand's disease. Am J Med 1976; 60:357.
32. Blatt PM, Brinkhous KM, Culp HR, Krauss SJ, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-co-factor activities. JAMA 1976; 236:2770.
33. Schwarz HP, Turecek PL, Pichler L, Mitterer A, Mundt W, Dorner F, Roussi J, Drouet L. Recombinant von Willebrand factor. Thromb Haemost 1997; 78:571.